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Abstract 
Marius R. Robciuc. Role of angiopoietin-like 3 and 4 in triacylglycerol metabolism. 
National Institute for Health and Welfare (THL). Research 83/2012. 150 pages. 
Helsinki, Finland 2012. 
ISBN 978-952-245-673-1 (printed); ISBN 978-952-245-674-8 (pdf) 
 
Triacylglycerols are the most efficient molecules for storing energy in living organ-
isms. Mammals obtain triacylglycerols either from the diet or they can synthesise 
them de novo, mainly in the liver. Gut and liver secrete triacylglycerols into the 
circulation packed in lipoproteins, such as chylomicrons and very low density lipo-
proteins, to be transported to other tissues. For storage, cell triacylglycerols are de-
posited in dynamic organelles called lipid droplets and in vertebrates adipocytes 
evolved as specialized cells to store large amounts of triacylglycerols. Excessive 
accumulation of triacylglycerols in circulation (hypertriglyceridemia) and/or in adi-
pose tissue (obesity) are major risk factors for type 2 diabetes and cardiovascular 
diseases, two major morbidities worldwide.  
The major enzymes governing the triacylglycerol metabolism are lipases, e.g. 
pancreatic lipase, lipoprotein lipase (LPL), hormone sensitive lipase and adipose 
triglyceride lipase. They catalyze the hydrolysis of triacylglycerols to release free 
fatty acids that are utilized further mainly for energy production or for storage. 
Angiopoietin-like (Angptl) proteins are a family of secreted factors suggested to 
be implicated in the regulation of lipid partitioning in the body. Of these, Angptl3 
and Angptl4 are potent regulators of LPL activity and plasma triacylglycerol con-
centration. In addition, they are suggested to enhance the breakdown of triacylgly-
cerol stores from adipose tissue in mice. 
This thesis extends our knowledge about the role of Angptl3 and Angptl4 in hu-
man triacylglycerol metabolism and provides mechanistic insights into the function 
of Angptl4 at cellular level. 
Most of the information about the role of Angptl3 and Angptl4 in human me-
tabolism has been obtained using genetic analysis approaches. Because these pro-
teins are highly processed at the post-transcriptional level and are secreted the aim 
was to measure the levels of Angptl3 and Angptl4 in plasma/serum and identify the 
relevant clinical correlates. For this two quantitative ELISAs were developed and 
validated to measure human Angptl3 and Angptl4. Studies performed using several 
population samples showed that circulating levels of Angptl3 and Angptl4 have no 
or minor effects on plasma triacylglycerol levels. In the case of Angptl3 only com-
plete absence of the protein in plasma, due to a nonsense mutation, generated dra-
matic changes not only in triacylglycerols but also in all major plasma lipoproteins 
and lipids, a phenotype referred to as familial combined hypolipidemia.  
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A role for Angptl4 in human obesity was suggested for the first time in this thesis 
by the study of monozygotic twins discordant for obesity. Serum Angptl4 and adi-
pose tissue ANGPTL4 mRNA levels are significantly decreased in obese twins as 
compared with their non-obese co-twins. In vitro experiments using human adipo-
cytes revealed that Angptl4 significantly increases the breakdown of triacylglycerol 
stores, a mechanism that might explain the observations in human subjects. 
Data obtained using animal models and human genetics clearly show that 
Angptl4 inhibits LPL activity and may modulate plasma triacylglycerol levels. Be-
cause the circulating levels of Angptl4 apparently do not influence LPL activity and 
plasma triacylglycerols, a question emerged whether Angptl4 can have more subtle 
roles at tissue level. In this thesis, studies using skeletal muscle cells in culture pro-
vided evidence that Angptl4 is part of a negative feedback mechanism that is likely 
to prevent the overload of cells with triacylglycerols. The data showed that free fatty 
acids, the products of LPL activity, act through peroxisome proliferator-activated 
receptor δ/retinoic X receptor to upregulate Angptl4 synthesis coupled to inhibition 
of LPL activity. Furthermore, Angptl4 appears to be regulated by insulin in a tissue 
specific manner suggesting a mechanism for insulin-mediated fuel partitioning in the 
body.    
Taken together this, data establish Angptl3 and Angptl4 as important regulators 
of triacylglycerol metabolism in humans. 
 
Keywords: Angiopoietin-like proteins, triacylglycerol, obesity, cardiovascular dis-
eases, dyslipidemia, lipolysis. 
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1 INTRODUCTION 
Triacylglycerol metabolism is currently under extensive investigation because of its 
critical role in the development of metabolic syndrome, obesity, diabetes and car-
diovascular disease (CVD), the leading causes of death worldwide. Triacylglycerol 
is a safe and efficient molecule to store fatty acids, which together with glucose are 
the major energy source for living organism. Because triacylglycerols are highly 
hydrophobic, they are stored in specialized organelles called lipid droplets that exist 
in all eukaryotic cells. In complex organisms triacylglycerols are transported be-
tween different tissues packed in lipoproteins. In mammals, plasma triacylglycerols 
are present mainly in the core of the triacylglycerol-rich lipoproteins (TRLs) such as 
chylomicrons and very low density lipoproteins (VLDL). Mobilisation of free fatty 
acids from triacylglycerol stored in lipid droplets or packed in lipoproteins is 
achieved by specialized enzymes called lipases.  
Lipoprotein lipase (LPL), bound to capillary endothelium, hydrolyzes the tria-
cylglycerols in chylomicrons or VLDL generating remnant particles. Remnants are 
rapidly cleared from circulation by the liver but some of them can penetrate the ves-
sel wall and contribute to the development of atherosclerosis (Proctor et al, 2004). 
Whether increased concentration of plasma triacylglycerol is an independent risk 
factor for cardiovascular disease has been a matter of debate for three decades. This 
is because hypertriglyceridemia is often part of the dyslipidemic profile including 
low high density lipoproteins (HDL) levels and elevated levels of small dense low 
density lipoproteins (LDL). It is now clear that elevated levels of triacylglycerol in 
plasma is an independent risk factor for the development of CVD and recently, 
statements from the European Atherosclerosis Society Consensus Panel and the 
American Heart Association have been published to update clinicians on this matter 
(Chapman et al, 2011; Miller et al, 2011). Severe elevations of plasma triacylgly-
cerols are observed in patients with familial combined hyperlipidemia (FCHL) and 
familial hypertriglyceridemia. FCHL is the most common genetic lipid disorder 
associated with increased risk for CVD affecting 0.5% - 2.0% of individuals in the 
general population (Gaddi et al, 2007). 
Chronic positive energy balance due to overnutrition and inactivity is common in 
our modern society and increasing. This leads to increased deposition of triacylgly-
cerol in adipose tissue and to the development of obesity. Obesity is a serious medi-
cal condition because it increases the risk of cardiovascular disease, type 2 diabetes, 
and some cancers, among other health problems. When the storage capacity of adi-
pose tissue is exceed other tissues, such as liver, skeletal muscle, heart and pancreas, 
become overloaded with triacylglycerols. If the oxidative and storage capabilities of 
the cells became saturated there is an accumulation of fatty acid intermediates, such 
as diacylglycerol and ceramide, that are likely to contribute to insulin resistance 
INTRODUCTION 
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(Samuel et al, 2010). Impaired insulin function leads to uncontrolled release of free 
fatty acids from adipose tissue, oversecretion of  triacylglycerol-rich VLDL particles 
(VLDL1) and delayed hepatic remnant clearance by the liver and impaired glucose 
uptake in skeletal muscle (Samuel et al, 2010).  
Important discoveries in the past decade have identified many key regulators of 
the triacylglycerol metabolism. Understanding the detailed mechanisms by which 
these molecules function will facilitate the development of new therapeutic  
strategies to restore the imbalance of triacylglycerol metabolism in obesity,  
diabetes and cardiovascular disease. 
 
? 
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2 REVIEW OF THE LITERATURE 
2.1 The triacylglycerol metabolism 
2.1.1 The triacylglycerol molecule 
 
Each triacylglycerol (also called triglyceride or fat) molecule is composed of three 
fatty acids bound through an oxyester bond to a single glycerol molecule (Figure 1). 
In nature the triacylglycerols are usually composed from two or more different fatty 
acids that can have differences in length and degree of saturation. Naturally occur-
ring triacylglycerols contain almost invariably long chain fatty acids with the ali-
phatic tail longer than 12 carbon atoms and in animals they reflect to some  
extent the composition of the diet (Perona et al, 2000).  
Because all three polar hydroxyl groups of glycerol form ester bonds with the 
polar carboxyl group of fatty acids, the triacylglycerol molecule is non-polar and 
highly hydrophobic. The hydrophobicity of triacylglycerol molecule confers an 
advantage as a storage molecule when compared with glycogen and starch (the stor-
age forms of glucose) that require hydration and thus weight more. In addition, the 
oxidation of triacylglycerol generates about six times more ATP as does the same 
quantity of glycogen. Therefore, humans that are overweight can use their triacyl-
glycerol stores to meet their energy needs for months, whereas the glycogen stores 
can provide energy for less than a day (Nelson & Cox, 2005).  
Although triacylglycerols serve mainly as energy reserve they also have other 
functions. The adipose tissue provides insulation for organisms and in some marine 
animals help to maintain buoyancy (Nelson & Cox, 2005). Normal triacylglycerol 
biosynthesis is critical for normal skin development and permeability barrier func-
tion (Stone et al, 2004). Moreover, triacylglycerol is the major fuel for brown adi-
pose tissue to maintain body temperature during cold exposure (Bartelt et al, 2011). 
Because triacylglycerol is chemically relatively inert, it can protect the cells from the 
potentially toxic effects of excess fatty acids. This is evident in tissues with limited 
capacity to store triacylglycerols, such as muscle and liver, where lipotoxicity is 
observed as they become overloaded with fatty acids (Muoio & Newgard, 2008). 
Triacylglycerols from seeds and fruits serve as valuable resources for industry, 
most recently as their potential to be used as biofuels. 
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Figure 1. Triacylglycerol molecule showing the Sn positions and the numeri-
cal and alphabetical nomenclatures of fatty acids (Manson & 
Weaver, 1997) (reprinted with permision from BMJ Publishing Group Ltd) 
2.1.2 Major sources for triacylglycerols 
 
Fatty acids stored in triacylglycerols can be synthesised de novo, mainly in the liver 
(endogenous source), or obtained from the diet by absorption in the intestine (exog-
enous source).  
For 2500 calorie intake daily it is generally recommended to consume 80-90 
grams of fat (triacylglycerols), of which more than 95% is absorbed in the intestine, 
mostly in the duodenum and proximal jejunum. Before absorption by enterocytes, 
triacylglycerols are emulsified in bile acid micelles and hydrolysed by pancreatic 
lipase/colipase complex at the positions sn-1 and sn-3 to produce  
2-monoacylglycerol and fatty acids (Mattson & Beck, 1956). Enterocytes can absorb 
2-monoacylglycerol and fatty acids by diffusion or specific transporters not clearly 
defined hitherto (Iqbal & Hussain, 2009). CD36 is the best characterized lipid trans-
porter that appears to have a key role in efficient utilisation of dietary fatty acids 
(Drover et al, 2005).   
Fatty acid synthase is a cytoplasmic enzyme responsible for the biosynthesis of 
fatty acids. Mammalian fatty acid synthase is active only as an intertwined dimer 
with two lateral semicircular reaction chambers for fatty acid elongation (Maier et 
al, 2006). Each monomer contains seven protein domains required for fatty acid 
synthesis: acyl carrier, acyl transferase, β-ketoacyl synthase, β-ketoacyl reductase, β-
hydroxylacyl dehydratase, enoyl reductase, and thioesterase.  Fatty acid synthase 
uses the glucose intermediate metabolite, acetyl coenzyme A (CoA), to synthesize 
REVIEW OF THE LITERATURE 
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unsaturated fatty acids such as palmitate (C16:0) and to a lesser extent longer or 
shorter fatty acids. 
Fatty acids, from de novo synthesis or diet, can enter the pathway of triacylglyc-
erol biosynthesis in the form of CoA esters and as partial acylglycerols.  
The glycerol for the initial esterification may be derived in the form of  
2-monoacylglycerols from lipolysis of triacylglycerols or in the form of dihydroxya-
cetone and glycerol-3-phosphate from glycolysis. Two major pathways for triacyl-
glycerol biosynthesis have been described more than 50 years ago: the glycerol 
phosphate pathway and the 2-monoacylglycerol pathway (Figure 2). The glycerol 
phosphate pathway is present in most tissues whereas the 2-monoacylglycerol path-
way occurs mainly in enterocytes, liver and adipose tissue. Both pathways are gov-
erned by acyltransferase and lipin enzymes that work in sequential steps shown 
figure 2.  Acyltransferases transfer one activated fatty acid (fatty acyl-coenzyme A, 
FA-CoA) to the glycerol backbone whereas lipin proteins have phosphatidate phos-
phatase activity and catalyze the formation of diacylglycerol in the glycerol-3-
phosphate pathway. 
 
 
 
Figure 2. Major pathways for triacylglycerol biosynthesis. GPAT, glycerol-
phosphate acyltransferase; AGPAT, acylglycerol-phosphate acyltrans-
ferase; MGAT, acyl CoA:monoacylglycerol acyltransferase; DGAT, dia-
cylglycerol acyltransferase. 
Newly synthesized triacylglycerols are thought to be released into the associated 
lipid bilayer and either stored in lipid droplets (in all tissues) or packed in lipopro-
teins (in hepatocytes and enterocytes) and secreted for transport to other tissues 
(Figure 3). 
 
REVIEW OF THE LITERATURE 
 
THL — Research 83/2012 20 ROLE OF ANGIOPOIETIN-LIKE 3 AND 4 IN 
TRIACYLGLYCEROL METABOLISM 
 
 
 
 
Figure 3. Hypothetical model illustrating the role of diacylglycerol acyltrans-
ferase (DGAT) enzymes in triacylglycerol synthesis in the ER (Yen et 
al, 2008). Triacylglycerol products of the DGAT reaction may be chan-
neled into the cores of cytosolic lipid droplets or triacylglycerol-rich lipo-
proteins for secretion in cells such as enterocytes and hepatocytes. (Re-
printed with permision from American Society for Biochemistry and Mo-
lecular Biology) 
2.1.3 Storage of triacylglycerols 
 
Lipid droplets are the major cellular organelles for the storage of triacylglycerols 
and other neutral lipids. Triacylglycerols are located in the core of the organelle and 
are separated from the aqueous phase of the cell by a monolayer of phospholipids. 
This structure is stabilized by structural proteins such as perilipin (Greenberg et al, 
1991). In addition to structural proteins, lipid droplets are decorated with lipid-
synthesis enzymes (e.g. diacylglycerol acyltransferase, DGAT2), lipases (e.g. hor-
mone sensitive lipase, HSL), and membrane-trafficking proteins (e.g. ras-related 
small GTP binding protein, Rab5). Several models for the biogenesis of lipid drop-
lets have been proposed and are depicted in figure 4. The common feature is that 
lipid droplets are generated at the endoplasmic reticulum (ER) membrane where 
neutral lipid-synthesizing enzymes (such as DGAT2) are located. As very dynamic 
organelles, lipid droplets enlarge by fusion and in adipocytes can reach more that 
100 µm in diameter (Bostrom et al, 2007; Walther & Farese, 2009). Moreover, they 
REVIEW OF THE LITERATURE 
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undergo fission, a process that might facilitate efficient intracellular lipolysis (Mar-
cinkiewicz et al, 2006).  
 
 
 
 
Figure 4. Models of lipid-droplet biogenesis (Walther & Farese, 2009). (Left) 
Model 1: Lipid droplet biogenesis by ER budding. Neutral lipids (orange) 
are synthesized by neutral lipid-synthesizing enzymes (NLSE) and bulge 
from the outer leaflet of the ER membrane (red). The nascent droplet 
may be coated by proteins (dark blue) that facilitate the budding process. 
(Middle) Model 2: Bilayer excision. Newly synthesized neutral lipids ac-
cumulate between the inner (blue) and outer (red) leaflets of the ER 
membrane and cause bulging. This entire lipid lens is then excised from 
the ER, leaving a transient hole in the membrane. ER contents (yellow) 
might leak through this hole into the cytosol. (Right) Model 3: Vesicular 
budding. A vesicle containing both leaflets of the ER membrane (red and 
blue) and a lumen (yellow) is formed by the vesicular budding machinery 
(green) at the ER membrane. The vesicle is subsequently tethered to the 
ER, where NLSEs (grey) fill the intramembranous space with neutral lip-
ids (orange). The luminal space (yellow) is compressed, and its contents 
may leak into the cytosol. This process may trap luminal proteins within a 
compartment of the lipid droplet. (Reprinted with permission from El-
sevier) 
2.1.4 Intracellular lipolysis  
 
Hydrolysis of stored triacylglycerols to glycerol and fatty acids is achieved by li-
pases in a process referred as intracellular lipolysis. Three lipases act at the lipid 
droplet surface in sequential actions for complete hydrolysis of triacylglycerol stores 
(Figure 5). Adipose triacylglycerol lipase (ATGL) is the rate limiting enzyme for the 
first step of lipolysis hydrolyzing triacylglycerol to diacylglycerol and fatty acid 
(Jenkins et al, 2004; Villena et al, 2004; Zimmermann et al, 2004). Hormone-
sensitive lipase (HSL or LIPE) is the rate limiting enzyme for the second step of 
lipolysis hydrolyzing diacylglycerol to monoacylglycerol and fatty acid (Haemmerle 
et al, 2002; Vaughan et al, 1964). The lipolysis is finalized after the hydrolyzis of 
monoacylglycerol to fatty acid and glycerol by the monoacylglycerol lipase (MGLL) 
(Karlsson et al, 1997; Tornqvist et al, 1972; Vaughan et al, 1964). ATGL, discov-
ered 40 years after the other two lipases, is the principal lipase responsible for basal 
levels of lipolysis since unphosphorylated HSL is predominately located in the cyto-
REVIEW OF THE LITERATURE 
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plasm (Egan et al, 1992; Lass et al, 2006). In adipose tissue, perilipin 1 is central in 
maintaining the basal levels of lipolysis by blocking the access of HSL to the lipid 
droplet surface and by sequestering the ATGL activator α/β hydrolase domain con-
taining 5/comparative gene identification-58 (ABHD5/CGI58) (Granneman et al, 
2007; Subramanian et al, 2004). Non-adipose tissues express little or no perilipin-1 
and other perilipins, such as perilipin 5 in oxidative tissues, might play an important 
role in the translocation of the lipases to lipid droplets and their interaction with 
activators (Granneman et al, 2009; Lass et al, 2011). 
Lipolysis is a tightly controlled process extensively investigated in adipose tis-
sue. Catecholamines, natriuretic peptides, and insulin are considered to represent the 
major regulators of lipolysis in human adipose tissue (Lafontan & Langin, 2009). 
Adrenaline and noradrenaline bind the β-adrenergic receptors coupled to stimulatory 
Gs proteins and activate adenylyl cyclase leading to a rise in intracellular cyclic 
adenosine monophosphate (cAMP) levels. In a similar fashion natriuretic peptide 
binds its receptor and increases intracellular cyclic guanosine monophosphate 
(cGMP) levels (Sengenes et al, 2000). The increased levels of intracellular cAMP 
and cGMP lead to the activation of protein kinase A (PKA) and protein kinase G 
(PKG), respectively. PKA and PKG phosphorylate HSL and perilipin 1 (PLINA) 
setting the stage for HSL to bind to the lipid droplet surface and increase its activity 
by up to 100-fold (Krintel et al, 2008; Schweiger et al, 2006; Stralfors & Belfrage, 
1985). Phosphorylation of perilipin 1 also causes the dislocation of the CGI-58 
available now to fully activate ATGL activity (Granneman et al, 2007; Subramanian 
et al, 2004). Human ATGL is also phosphorylated in a PKA independent manner, 
however, the relevance of phosphorylation in the regulation of enzyme activity is 
unclear (Lass et al, 2011; Zimmermann et al, 2004). In contrast to catecholamines, 
insulin promotes cAMP degradation upon binding to the insulin receptors and stimu-
lation of the phosphodiesterase-3B (PDE-3B) hence intracellular lipolysis is in-
hibited. To date, no evidence exists that cellular MGLL mRNA concentrations or 
enzyme activities are regulated by either hormones or the energy state of the cell 
(Lass et al, 2011). 
Since all cells can store triacylglycerols in lipid droplets they are also equipped 
with the basic lipolytic machinery although some of the components and regulatory 
pathways are different (Lass et al, 2011).   
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Figure 5. Control of Human Adipocyte Lipolysis. Binding of catecholamines to 
Gs protein-coupled b1/2-adrenoceptors stimulates cAMP production by 
adenylyl cyclase (AC) and activates protein kinase A (PKA). Insulin fa-
vors cAMP degradation through activation of phosphatidylinositol-3 phos-
phate kinase (PI3-K) and protein kinase B (PKB) and stimulation of phos-
phodiesterase 3B (PDE-3B) activity. Natriuretic peptides promote cGMP 
accumulation and protein kinase G (PKG) activation. PKA and PKG 
phosphorylate hormone-sensitive lipase (HSL) and perilipin 1 (PLINA). 
Adipose triglyceride lipase (ATGL) and monoglyceride lipase (MGL) are 
also participating in the hydrolysis of triglycerides (modified after (Langin, 
2010). 
2.1.5 Transport of triacylglycerols  
 
Triacylglycerols are transported in large macromolecular complexes of lipids and 
proteins called lipoproteins. The function of lipoproteins is to transport water insol-
uble lipids such as triacylglycerols and cholesteryl esters in circulation. The struc-
ture of lipoproteins resembles that of lipid droplets with a monolayer of phospho-
lipids stabilised by apolipoproteins such as apolipoprotein B (apoB) and a core con-
taining neutral lipids. Triacylglycerols are mainly transported in triacylglycerol-rich 
lipoproteins (TRLs), namely very low density lipoproteins (VLDL) and chylomi-
crons. VLDL are secreted by the liver in plasma whereas chylomicrons are secreted 
by the small intestine into the lymph.  
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Chylomicrons, assembled in enterocytes, are stabilised by a shorter form of 
apolipoprotein B, apoB48, produced via a specific RNA editing mechanism (Powell 
et al, 1987). The lipidation of apoB48 has many similarities with two-steps VLDL 
production in the liver (Cartwright & Higgins, 2001). In the first step newly syn-
thesized apoB48 is lipidated by microsomal triglyceride transfer protein (MTP) at 
the inner leaflet of the endoplasmic reticulum (ER). The second step is initiated after 
poorly lipidated apoB48 detach from the ER membrane to form a “primordial parti-
cle” (Mansbach & Gorelick, 2007). Further enlargement of the particle occurs by 
MTP-dependent lipidation or fusion with preformed lipid droplets in a process 
termed “core expansion” (Hussain, 2000). These steps generate pre-chylomicrons 
which are packed in special vesicles called prechylomicron transport vesicles 
(PCTV) and transported to Golgi apparatus before secretion in the lymph (Cart-
wright & Higgins, 2001; Cartwright et al, 2000; Siddiqi et al, 2003). The formation 
of PCTV is coat protein complex II (COPII)-independent and distinct from vesicles 
that transport proteins (Siddiqi et al, 2003). An important feature of PCTV that fur-
ther distinguishes them from protein vesicles is the presence of v-SNARE and vesi-
cle associated membrane protein 7 (VAMP7) which facilitates the fusion with cis-
Golgi (Mansbach & Gorelick, 2007; Siddiqi et al, 2006).  
VLDL is assembled within the secretory pathway of hepatocytes in two major 
steps (Olofsson et al, 2000) (Figure 6). The first step occurs in the rough ER where 
MTP lipidates apoB co- and post-translationally forming pre-VLDL (Boren et al, 
1992; Sharp et al, 1993; Wetterau et al, 1992). If the lipidation is inadequate apoB is 
exposed to the cytosol, recognised by chaperones such as heat shock protein 70 
(Hsp70) as a misfolded protein, ubiquitinated and degraded mainly via the ubi-
quitin–proteasome system (Fisher et al, 1997). Properly lipidated pre-VLDL is con-
verted to VLDL2 by further lipidation in the second step of VLDL biogenesis 
(Olofsson et al, 2000). This occurs in the smooth ER compartment during the as-
sembly of VLDL2 in Sar1/COPII vesicles. VLDL2 containing vesicles are trans-
ported to Golgi apparatus, a process dependent on ADP ribosylation factor 1 (ARF-
1). In Golgi apparatus VLDL2 is either secreted in plasma or acquire a major propor-
tion of triglycerides and form VLDL1. Formation of VLDL1 is dependent on phos-
pholipase D1 (PLD1) and extracellular signal regulated kinase 2 (ERK2) (Andersson 
et al, 2006; Verges, 2010). VLDL1 is also secreted in plasma and high levels are 
associated with insulin resistance and type 2 diabetes (Taskinen, 2003). 
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Figure 6. VLDL assembly and secretion (Verges, 2010). First step: in the rough 
endoplasmic reticulum (ER), apoB is lipidated by the microsomal transfer 
protein (MTP), leading to the formation of pre-VLDL. Second step: pre-
VLDL is further lipidated to form VLDL2. VLDL2 exits the ER compart-
ment by Sar1/COPII vesicles, which are directed to the Golgi apparatus. 
ADP ribosylation factor 1 (ARF-1) is involved in VLDL2  
trafficking between the ER and the Golgi apparatus. In the Golgi appara-
tus, VLDL2 is converted to larger VLDL1 by addition of lipids. This step is 
promoted by Phospholipase D1 and ERK2. FA: fatty acid, FFA: free fatty 
acid, apoB: apolipoprotein B, VLDL: very low density lipoprotein, TG: 
triglycerides, ER: endoplasmic reticulum, MTP: microsomal transfer pro-
tein, ARF-1: ADP ribosylation factor 1, ERK2: extracellular signal-
regulated kinase 2. (Reprinted with permission from Elsevier). 
 
VLDL and chylomicrons acquire other proteins (mostly exchangeable apolipo-
proteins) on their surface, either intracellularly or in systemic circulation, that are 
critical for their metabolism. Remodelling of TRLs in systemic circulation is very 
complex and not completely understood but the rate limiting enzyme responsible for 
the delivery of triacylglycerol fatty acids to peripheral tissues is lipoprotein lipase 
(LPL).      
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2.1.6 Lipoprotein lipase  
 
LPL is a member of extracellular lipase family that also includes pancreatic lipase, 
hepatic lipase and endothelial lipase (Olivecrona & Olivecrona, 2009). The active 
form of LPL is a head-to-tail dimer stabilized by noncovalent interactions (van Til-
beurgh et al, 1994; Wong et al, 1997). Formation of active LPL dimer is facilitated 
by a specific chaperone called lipase maturation factor 1 (LMF1) (Peterfy et al, 
2007). LPL dimer is unstable under physiological conditions suggesting that it is 
spring-loaded and endowed with a built-in mechanism of self-destruction (Osborne 
et al, 1985). This is an important property for an enzyme that acts extracellularly but 
whose activity needs to be rapidly regulated (Olivecrona & Olivecrona, 2009). This 
property is used by the LPL inhibitor angiopoietin-like 4 (Angptl4) that interacts 
with the dimer and triggers the formation of inactive monomers (Sukonina et al, 
2006).   
LPL exerts its function bound to the luminal surface of capillaries, within heart, 
white and brown adipose tissue, and skeletal muscle, where it binds TRLs and hy-
drolyses their triacylglycerol core to release fatty acids for use by parenchymal cells 
(Figure 7). Because LPL is synthesised in parenchymal cells it has to be transported 
to the luminal side of the endothelium to function efficiently. Due to a large number 
of positively charged amino acid residues in its structure, secreted LPL is retained in 
the glycocalyx bound to heparan sulfate proteoglycans (HSPG). Glycosylphospha-
tidylinositol-anchored high density lipoprotein–binding protein 1 (GPIHBP1), a 
GPI-anchored protein produced by capillary endothelial cells, binds LPL with higher 
affinity than HSPG in the subendothelial space and transports it to the capillary lu-
men (Figure 7) (Beigneux et al, 2007; Davies et al, 2010). The mechanisms of li-
polysis at the endothelium surface is not yet defined but it might involve the cluster-
ing of LPL by GPIHBP1 in caveolae (Young et al, 2011). 
LPL delivers the triacylglycerols to the tissues mainly after hydrolysis of core 
triglycerides in TRLs. In this process, chylomicrons and VLDL are converted to 
chylomicron remnants (CR) and intermediate density lipoproteins (IDL) whereas 
triacylglycerol is hydrolysed to fatty acids and a 2-monoglyceride (Hassing et al, 
2011; Morley & Kuksis, 1972). CR and IDL are rapidly cleared by the liver or, in 
the case of IDL, it is also converted further to low density lipoproteins (LDL). Pro-
ducts of triacylglycerol hydrolysis are rapidly taken up by the adjacent parenchymal 
tissue, although a significant amount of fatty acids is released in plasma as albumin 
bound fatty acids (Bickerton et al, 2007; Hultin et al, 1996). Besides its hydrolytic 
activity, LPL can facilitate the uptake of triacylglycerol in cells also by enhancing 
the endocytosis of lipoprotein particles (Fernandez-Borja et al, 1996; Merkel et al, 
2002; Olivecrona & Olivecrona, 2009). 
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Figure 7. LPL mediated hydrolysis of plasma triacylglycerol. LPL is synthe-
sized in parenchymal cells (such as adipocytes, cardiomyocytes and 
myofibrils), maturated by lipase maturation factor 1 (LMF1) and secreted 
in the subendothelial space where it binds to heparane sulfate proteogly-
cans (HSPGs). Glycosylphosphatidylinositol-anchored high density lipo-
protein–binding protein 1 (GPIHBP1) binds LPL with higher affinity than 
HSPGs  and transport it at the luminal site of the capillary. LPL, located 
probably in lipid rafts bound to GPIHBP1, engages VLDL and chylomi-
crons (CM) and hydrolyses their triacylglycerol to generate remnants 
(CR) and IDL, respectively. Most of the fatty acids generated by LPL are 
rapidly taken up by adjacent parenchymal tissue although a significant 
amount of is released in plasma as albumin bound fatty acids. The fatty 
acids will be locally internalized by fatty acid transporters such as CD-36. 
LPL activity is pivotal in maintaining the physiological distribution of triacylgly-
cerols among tissues in response to energy requirements and hormonal changes. For 
this, LPL is regulated at transcriptional, posttranscriptional, translational, and post-
translational levels in a tissue-specific manner (Wang & Eckel, 2009). Studies in 
mice provided evidence that altered LPL expression and regulation has major meta-
bolic consequences on macronutrient fuel partitioning, energy homeostasis, insulin 
action, and lipoprotein metabolism (Wang & Eckel, 2009). 
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2.2 Angiopoietin-like family 
 
The angiopoietin-like (Angptl) protein family comprises of seven secreted mol-
ecules which have structural similarities with angiopoietins (Conklin et al, 1999; 
Kersten et al, 2000; Kim et al, 2000; Kim et al, 1999a; Kim et al, 1999b; Oike et al, 
2003; Peek et al, 2002; Yoon et al, 2000). The structure of Angptls is predicted to 
contain an N-terminal coiled-coil domain (CCD) and a C-terminal fibrinogen-like 
domain (FLD) (Figure 8) (Davis et al, 2003; Mattijssen & Kersten, 2011). Biochem-
ical analyses suggest that at least some Angptls also form oligomers via the CCD as 
it is the case with angiopoietins (Figure 8) (Davis et al, 2003; Ge et al, 2005; Ge et al, 
2004a). 
 
 
 
 
Figure 8. Structure of angiopoietin oligomers (Davis et al, 2003). Schematic 
representations of angiopoietin structures (top) and transmission electron mi-
croscopy visualization (bottom) of Angiopoietin1 oligomers. Fibrinogen-
like domain (FLD), Coiled-coil domain (CCD). Modified after Davis et al, 
2003. (Reprinted with permission from Nature Publishing Group). 
Although Angptl molecules share similar domain structures with angiopoietins, they 
do not bind to the tyrosine-protein kinase receptors, TIE2 or TIE1 (Augustin et al, 
2009; Kim et al, 1999a; Kim et al, 1999b). FLDs of Angptls are expected to function 
as signaling molecules and hitherto several studies have shown that they bind and 
signal via integrins (Camenisch et al, 2002; Tabata et al, 2009; Zhang et al, 2006; 
Zhu et al, 2011). In contrast to angiopoietins, Angptls are proteolytically cleaved by 
proprotein convertases to release the FLD and CCD (Figure 8) (Ge et al, 2004a; Ono 
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et al, 2003). It was suggested that the proteolytic cleavage of Angptls can potentiate 
some of their functions (Chomel et al, 2009; Ono et al, 2003; Schjoldager et al, 
2010), thus it can be an important regulatory step in the mechanism of action of 
Angptls that remains to be established. Most of the knowledge we have about 
Angptls comes from studies on Angptl3 and Angptl4, but it is expected that post-
translational modifications like oligomerisation and cleavage play an important role 
for the function of other Angptls as well. 
Angptls are pleiotropic molecules involved in angiogenesis, tumor metastasis, 
wound healing, appetite control and lipid and glucose metabolism (Goh et al, 2010; 
Hato et al, 2008; Kim et al, 2010; Mattijssen & Kersten, 2011). Population studies in 
humans and functional studies in animal models have shown that Angptl3 and 
Angptl4 are potent regulators of triacylglycerol metabolism but their mechanism of 
action is not completely understood.  
 
 
 
 
Figure 9. Phylogenetic trees for Angptls and angiopoietins (Angpt) (Hato et al, 
2008). (Reprinted with permission from Elsevier). 
 
2.2.1 Angiopoietin-like 3 
 
Conklin and collaborators discovered Angptl3 in 1999 while searching the expressed 
sequence tags databases for signal sequences and amphipathic helices (Conklin et al, 
1999). Mouse Angptl3 gene is located on chromosome 4 spanning 9404 bp, with 7 
exons encoding a 455 amino acids secreted protein. The human ANGPTL3 gene is 
located on chromosome 1 (1p31.1-p22.3) spanning 7994 bp and encodes a 460 AA 
protein.  
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Figure 10. Schematic representation of Angptl3 modular structure (Ono et al, 
2003). (Reprinted with permission from American Society for Biochemis-
try and Molecular Biology) 
2.2.1.1 Transcriptional regulation 
 
ANGPTL3 is expressed almost exclusively in the liver, with minor expression found 
in the kidney (Romeo et al, 2009). An important regulator of Angptl3 expression is 
liver X receptor (LXR), a nuclear receptor activated by oxysterols that control whole 
body cholesterol and lipid homoeostasis (Kaplan et al, 2003).  LXR response ele-
ment is located within the promoter of ANGPTL3 and it is likely that some of the 
effects of LXR on lipid metabolism are mediated by Angptl3 (Inaba et al, 2003). 
Several other molecules have been implicated in the control of ANGPTL3 gene 
expression, e.g. peroxisome proliferator-activated receptor delta (PPAR) δ, insulin, 
leptin, thyroid hormone and lipopolysaccharide (Fugier et al, 2006; Lu et al, 2010; 
Matsusue et al, 2006; Shimamura et al, 2004). 
 
2.2.1.2 Post-translational modifications 
 
Angptl3 undergoes several post-translational modifications such as oligomerisation, 
cleavage and glycosylation. Angptl3 forms oligomers, a feature that is shared with 
angiopoietins (Figure 8), but the importance of the modification for protein function 
or turnover is currently not known. Proprotein convertases cleave Angptl3 at two 
sites in the linker region, Arg221/Ala222 and Arg224/Thr225, to generate the CCD and 
FLD and to activate its function (Figure 10) (Ono et al, 2003). Interestingly, Angptl3 
is O-glycosylated at Thr226 by UDP-GalNAc: polypeptide N-
acetylgalactosaminyltransferase 2 (GalNAc-T2) modification that reduces Angptl3 
cleavage and possibly its function (Ono et al, 2003; Schjoldager et al, 2010). Vari-
ants in the GALNT2 gene are associated with increased triacylglycerol levels in ge-
nome wide association studies (GWAS) possibly due to altered GalNac-T2-
mediated O-glycosylation of Angptl3 (Hegele et al, 2009; Schjoldager et al, 2010; 
Teslovich et al, 2010). Lack of GalNac-T2 would be expected to reduce O-
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glycosylation and increase the cleavage of Angptl3, which inhibits the LPL activity, 
and thus, increases triacylglycerol levels. This interesting possibility was not re-
cently confirmed in carriers of GALNT2 loss-of-function mutations where reduced 
plasma triacylglycerols levels and no difference in Angptl3 processing were ob-
served (Holleboom et al, 2011). 
 
2.2.1.3 Inhibition of lipoprotein lipase 
 
The best understood function of Angptl3 is regulation of plasma triacylglycerol 
levels mainly by LPL inhibition. This was first demonstrated in KK/San mice that 
have low plasma triacylglycerol levels due to a 4-bp insert in exon 6 of the Angptl3 
gene, creating a stop codon at position 347 (Koishi et al, 2002). Koshi and col-
leagues demonstrated that overexpression of Angptl3 or intravenous injection of the 
purified protein in KK/San or C57BL/6 J mice elicited an increase in plasma triacyl-
glycerol levels (Koishi et al, 2002). Same group demonstrated further that the 
phenotype in KK/San mice is mainly due to enhanced clearance of VLDL with 
small to no differences in hepatic VLDL secretion rate (Shimizugawa et al, 2002). 
Furthermore, in vitro analysis revealed that Angptl3 directly inhibits LPL activity in 
a concentration dependent manner (Shimizugawa et al, 2002) whereas in vivo tar-
geted disruption of Angptl3 increased post heparin plasma LPL activity (Koster et al, 
2005). The increase in plasma triacylglycerol levels by Angptl3 is most prominent 
during the fed state, suggesting that Angptl3 mainly plays a role in regulation of 
peripheral lipid uptake after feeding (Koster et al, 2005). In contrast to in vivo effect, 
Angptl3 inhibits LPL activity weakly and reversibly in vitro possibly because of 
Angptl3-induced cleavage of LPL (Liu et al, 2010; Shan et al, 2009).  Cell-based 
analysis showed that Angptl3 enhances the cleavage of LPL by paired amino acid 
converting enzyme-4 (PACE4) and furin causing dissociation of LPL from the cell 
surface (Liu et al, 2010). It appears that HSPG and GPIHBP1 protect LPL activity 
from Angptl3 inhibition but not from Angptl3-induced LPL cleavage (Liu et al, 
2010; Shan et al, 2009; Sonnenburg et al, 2009).  
 
2.2.1.4 Human genetic studies 
 
Genome wide association studies (GWAS) in humans have shown that single nu-
cleotide polymorphisms (SNPs) at loci near the ANGPTL3 are associated with 
plasma concentration of triacylglycerol (Kathiresan et al, 2008; Teslovich et al, 2010; 
Willer et al, 2008).  One ANGPTL3 SNP identified in GWAS, rs12130333, is also 
associated with the Fredrickson hyperlipoproteinemia type 5, representing a mixed 
hyperlipidaemia characterized by elevated VLDL and chylomicron levels (Hegele et 
al, 2009). Re-sequencing of the seven exons of ANGPTL3 in the Dallas Heart Study 
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showed further evidence for a link between the ANGPTL3 gene and plasma triacyl-
glycerol levels in humans (Romeo et al, 2009). All sequences predicted to be loss-
of-function alleles (frameshift 122 [Fs122], FsQ192, and FsK455) were identified in 
the lowest quartile of triacylglycerol levels, suggesting that deficiency in Angptl3 is 
associated with reduced triacylglycerol levels in plasma (Romeo et al, 2009). Fur-
thermore, Musunuru et al. identified E128X and S17X as two novel nonsense muta-
tions in ANGPTL3 by sequencing the exome of two individuals with familial com-
bined hypolipidemia, a phenotype characterized by a dramatic reduction in all major 
plasma lipoproteins (Musunuru et al, 2010). Lipoprotein metabolic studies in hu-
mans suggested that Angptl3 deficiency decreases VLDL production rate, contribut-
ing to the low triacylglycerol levels in plasma (Musunuru et al, 2010). Thus, human 
genetic studies clearly link the ANGPTL3 gene to regulation of plasma lipid levels, 
with a primary effect on plasma triacylglycerol. 
 
2.2.1.5 Mobilization of triacylglycerol stores 
 
Angptl3 deficiency in mice was shown to decrease plasma free fatty acids whereas 
injection of recombinant or adenoviral overexpression of Angptl3 robustly increased 
plasma free fatty acids (Koishi et al, 2002). This effect is explained by the increased 
in intracellular adipose tissue lipolysis (Shimamura et al, 2003). Indeed, Angptl3 
binds to adipocyte surface and triggers the release of free fatty acids. Interaction 
with the surface of adipocyte was dependent on HSPGs, as the addition of soluble 
heparin greatly reduced the Angptl3 binding (Shimamura et al, 2003). If the same 
would happen in humans, it provides a mechanism for the decreased VLDL produc-
tion rate observed in familial combined hypolipidemia (Musunuru et al, 2010). A 
decrease flux of free fatty acids from adipose tissue to the liver, due to Angptl3 defi-
ciency, is expected to decrease the VLDL secretion (Gibbons et al, 2000; Taskinen, 
2003). Therefore, Angptl3 is potentially an important factor in the crosstalk between 
adipose tissue and liver to regulate whole body triacylglycerol homeostasis.   
 
2.2.1.6 Other functions 
 
In addition to its role as LPL inhibitor, Angptl3 is able to inhibit endothelial lipase 
(EL), an enzyme involved in high density lipoprotein (HDL) catabolism, therefore 
plasma Angptl3 levels are positively correlated with HDL cholesterol and phospho-
lipid levels (Shimamura et al, 2007). The suggested mechanism involves activating 
cleavage of Angptl3 by hepatic proprotein convertases (Jin et al, 2007). Angptl3 
cleavage and function was shown to be inhibited both in vitro and in vivo by 
profurin, an intracellular inhibitor of proprotein convertases (Jin et al, 2007). 
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If the Angptl3-CCD is implicated in the inhibition of LPL and EL, the FLD gives 
Angptl3 proangiogenic properties (Camenisch et al, 2002). Angptl3-FLD was shown 
to bind alpha(v)beta(3) integrin and to induce angiogenesis in vivo (Camenisch et al, 
2002).  
 
2.2.2 Angiopoietin-like 4  
 
Kim et al. identified Angptl4 using degenerate PCR of a human embryonic cDNA to 
obtain a product with a novel sequence related to the angiopoietins (Kim et al, 2000). 
Concurrently, Angptl4 was isolated and characterized as a novel target for the nu-
clear receptors PPARγ and PPARα (Kersten et al, 2000; Yoon et al, 2000). 
Mouse Angptl4 is located on chromosome 17 and has 7 exons encoding for a 410 
amino acids protein. The human ANGPTL4 is located on chromosome 19 (19p13.3), 
has a similar organisation with mouse Angptl4 and encodes a 406 amino acid protein. 
 
2.2.2.1 Transcriptional regulation 
 
In contrast to Angptl3, Angptl4 is ubiquitously expressed but the tissue with highest 
expression for humans is liver and for mice the adipose tissue (Kersten et al, 2000; 
Romeo et al, 2009). As it was originally discovered, the ANGPTL4 gene is a target 
of PPARα and -γ in liver and adipose tissue, respectively (Kersten et al, 2000; Yoon 
et al, 2000). In other tissues like skeletal and cardiac muscle, PPARδ is a main regu-
lator of Angptl4 expression (Georgiadi et al, 2010; Staiger et al, 2009). Accordingly, 
ANGPTL4 is the most highly induced gene by fatty acids, activators of PPARs, in 
several cell types (Georgiadi et al, 2010; Mattijssen & Kersten, 2011; Staiger et al, 
2009). Other stimuli such as transforming growth factor β (TGFβ), insulin, hypoxia 
or glucocorticoids can also control Angptl4 expression in various cell types (Koli-
wad et al, 2009; Le Jan et al, 2003; Padua et al, 2008; Yamada et al, 2006). 
 
2.2.2.2 Post-translational modifications 
 
Angptl4 is cleaved at the conserved proprotein convertase recognition sequence 
161RRKR164 to generate an N-terminal CCD and a C-terminal FLD (Figure 11) (Ge 
et al, 2004a; Yin et al, 2009). Proprotein convertases (PC), such as furin, PC5/6, 
PACE4, and PC7, are all able to cleave human Angptl4 at a consensus site but 
whether this is important for Angptl4 function is not clear (Lei et al, 2011; Yin et al, 
2009). Angptl4 forms oligomers intracellularly, before secretion, in a process de-
pendent on disulfide bonds (Ge et al, 2004a; Yin et al, 2009). Since oligomerisation 
is a property given by the CCD, both full length and N-terminal fragment can be 
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detected as oligomers secreted by the cells under nonreducing gel electrophoresis 
(Ge et al, 2004a; Yin et al, 2009). In addition, N-glycosylation of FLD was sug-
gested to play an important role in Angptl4 angiogenic potential whereas sialylation 
of Angptl4 impact the glomerular ultrafiltration (Clement et al, 2010; Yang et al, 
2008). 
 
 
 
Figure 11. Schematic representation of Angptl4 modular structure  
 
2.2.2.3 Inhibition of lipoprotein lipase 
 
The first hint about Angptl4 function was provided by Yoshida et al. in 2002. They 
reported an increase in plasma lipid levels after intravenous injection of the Angptl4 
protein in KK/San mice, as well as an inhibition of LPL activity in vitro (Yoshida et 
al, 2002). Further studies provided convincing evidence that Angptl4 increases 
plasma triacylglycerol levels in mice by inhibiting LPL activity (Ge et al, 2004b; 
Koster et al, 2005; Xu et al, 2005; Yu et al, 2005). The mechanism by which 
Angptl4 inhibits LPL activity proved to be very interesting. The CCD of Angptl4 
inhibits LPL by promoting the conversion of catalytically active LPL dimers into 
catalytically inactive LPL monomers, thereby permanently inactivating LPL (Su-
konina et al, 2006). In mice, injection of monoclonal antibody directed against the 
CCD of Angptl4 lowers plasma TG to levels comparable to Angptl4−/− animals 
(Desai et al, 2007). Further studies established that the CCD of Angptl4 irreversibly 
inhibits LPL activity at least partially by generation of inactive monomers (Shan et 
al, 2009; Yau et al, 2009). Recently, it was reported that Angptl4 CCD stimulates 
LPL proteolysis by cell associated proprotein (Lei et al, 2011). It is tempting to 
speculate that the latter mechanism is secondary to the generation of inactive 
monomers. The LPL monomers have lower affinity to heparin and might be more 
susceptible to proteolysis, as it is the case with Angptl4 (Chomel et al, 2009). 
2.2.2.4 Human genetic studies 
 
Evidence for a role of Angptl4 in regulating plasma TG homeostasis in humans 
came together with a technological breakthrough as ANGPTL4 was resequenced in a 
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large number of individuals (n = 3,551) (Romeo et al, 2007). One variant, E40K, 
was identified as present in approximately 3% of European Americans and associ-
ated with significantly lower plasma levels of triacylglycerol and higher levels of 
HDL (Romeo et al, 2007). The finding was replicated by other groups and interest-
ingly, differences between E40K carriers and non-carriers persisted over a nine-year 
period during which triacylglycerol concentrations went up in both groups (Nettle-
ton et al, 2008; Talmud et al, 2008). Surprisingly, these findings are not supported 
by the recent GWAS studies that associated ANGPTL4 with HDL rather than tria-
cylglycerol levels in plasma (Kathiresan et al, 2008; Teslovich et al, 2010). 
 
2.2.2.5 Mobilization of triacylglycerol stores 
 
Besides raising circulating triacylglycerol levels, Angptl4 potently increases intra-
cellular adipose tissue lipolysis. Injection of recombinant Angptl4 in mice acutely 
raises free fatty acids, suggesting enhanced breakdown of triacylglycerols in adipose 
tissue (Yoshida et al, 2002). In accordance with this, Angptl4 overexpression aug-
ments the fasting-induced increase in free fatty acids, whereas this response is com-
pletely blunted in Angptl4−/− mice (Sanderson et al, 2009). Furthermore, very re-
cent data established Angptl4 as a physiological mediator of intracellular lipolysis in 
murine adipocytes during fasting (Gray et al, 2012). Angptl4 was shown to be ne-
cessary for the ability of glucocorticoids and catecholamines to mobilize the fatty 
acids from triacylglycerol stores in adipocytes (Gray et al, 2012). This is achieved 
by Angptl4-dependent increase in adipose tissue cAMP levels and the phosphoryla-
tion of cAMP-dependent components of the lipolytic machinery, such as HSL and 
PLIN1 (Gray et al, 2012). As FLD and CCD mediate different Angptl4 functions, it 
will be interesting to know which is responsible for stimulation of intracellular li-
polysis in adipocytes and if cleavage is an important regulatory step. As Angptl4 is 
expressed and secreted from most of the tissues, it remains to be seen if it is func-
tioning in an endocrine or autocrine/paracrine manner. Further research is also ne-
cessary to determine if interaction with integrins and HSPGs play an important role 
in this process. 
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2.2.2.6 Other functions 
 
In the recent years, Angptl4 has emerged as a multifunctional protein and important 
regulator of physiological and pathological processes in a variety of tissues.  
Angptl4 is expressed in the mouse hypothalamus, cortex and pituitary gland, and 
was suggested to function as an anorexigenic factor (Kim et al, 2010; Wiesner et al, 
2004). Administration of Angptl4 lowered food intake and body weight gain pos-
sibly via inhibition of hypothalamic AMPK activity (Kim et al, 2010). It will be 
interesting to see how Angptl4 function in hypothalamus is coordinated with its 
activity in mobilizing triacylglycerol stores from adipose tissue (Gray et al, 2012; 
Mandard et al, 2006). Moreover, fibrinogen-like domain of Angptl4 was shown to 
interact and activate specific integrins in order to modulate wound healing, angio-
genesis, vascular permeability and tumorigenesis (Goh et al, 2010; Le Jan et al, 2003; 
Padua et al, 2008; Zhu et al, 2011). 
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3 AIMS OF THE STUDY 
The aim of this work was to understand the roles of Angptl3 and Angptl4 in the 
regulation of human energy and lipoprotein metabolism and their impact on obesity 
and cardiovascular diseases using population samples and cell biological approach. 
 
Specific goals of the thesis were: 
 
1. to develop and validate quantitative methods for the measurement of 
Angptl3 and Angptl4 in humans; 
2. to determine the correlations between Angptl3 and Angptl4 in human 
plasma with risk factors for cardiovascular diseases and obesity;  
3. to determine the mechanisms for tissue specific regulation and function of 
Angptl4.  
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4 MATERIALS AND METHODS 
 
4.1 Published methods 
 
List of published methods 
Method Original publication 
AAV gene delivery in vivo and in vitro III 
Affinity chromatography I 
ELISA I, II, III, IV 
Fatty acid oxidation III 
Fluorescence microscopy III 
Glucose uptake III 
Glycogen synthesis III 
LPL activity assay III 
Microarray analysis IV 
Oil Red O staining III 
Plasma lipid measurements I, II, III, IV 
Real time PCR III 
RNA extraction III 
RNA interference III 
RT-PCR III 
SDS-PAGE and Western blot I, II, III 
Statistical analyses I, II, III, IV 
Transient transfection I, II, III 
 
 
Health 2000 Health Examination Survey (original paper I) 
Health 2000 Health Examination Survey was carried out in Finland from fall 2000 
to spring 2001 (Aromaa & Koskinen, 2002). Serum samples from a random sub-
sample consisting of 250 subjects (125 men and 125 women), age range 30 – 94 
years was used to study the correlations between Angptl3 and Angptl4 and major 
plasma lipid levels.  
 
Northwick Park Heart Study II (original paper II) 
Northwick Park Heart Study II (NPHSII) is a population-based prospective cohort 
comprising of 3012 European Caucasian men aged 50-63 years recruited from nine 
general medical practices in the United Kingdom (Robertson et al, 2003). Individu-
als were excluded if they had pre-existing cardiovascular disease (coronary heart 
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disease or stroke), coronary surgery or malignant disease, or were taking Aspirin or 
anticoagulant. Subjects were followed for the development of coronary heart disease 
from 1989. Six SNPs were used to genotype NPHSII: rs4076317 (-207C>G), 
rs7255436 (3991A>C), rs1044250 (6959C>T, T266M), rs11672433 (9511A>G), 
rs7252574 (12574C>T), and rs1808536 (12651G>A), in addition to E40K (118G>A) 
(Talmud et al, 2008). These SNPs captured >92% of the genetic variation in 
ANGPTL4. Genotyping in NPHSII was performed using TaqMan technology (Ap-
plied Biosciences, ABI, Warrington UK) as previously reported (Talmud et al, 2008). 
Based on their T266M genotype, 666 subjects were selected to study the relationship 
between Angptl4 levels and plasma triglycerides. 
 
FinnTwin12 and FinnTwin16 studies (original paper IV) 
For this study, 121 twin pairs (46 monozygotic and 75 dizygotic) were selected from 
two population-based longitudinal studies, FinnTwin16 (FT16) and FinnTwin12 
(FT12) each consisting of five consecutive birth cohorts of Finnish twins (n=5601 
subjects in FT16 and n=5184 in FT12) (Kaprio, 2006). Of the 121 pairs studied, 21 
monozygotic pairs and 48 dizygotic pairs were discordant for obesity with intra-pair 
difference in BMI ≥ 2.5 kg/m2, and one twin obese (BMI ≥ 30) and the other co-twin 
non-obese. Their weight had been stable for at least three months prior to the study. 
Weight and height were measured after 12-hour overnight fast barefoot and in light 
clothing to calculate BMI. BMI ≥25 kg/m2 was used as a cut-off for overweight and 
BMI ≥30 kg/m2 as a cut-off for obesity. Body composition was measured using 
whole body DXA scans. Serum Angptl4 concentration and adipose tissue ANGPTL4 
expression of were studied in relationship with obesity-related parameters.  
 
Statistical analyses 
 SPSS version 16.0 or 17.0 for Windows (SPSS, Inc.) and GraphPad Prism 4.03 
(GraphPad Software, Inc.) were used to perform the statistical analyses. Parameters 
were logarithmically transformed before Pearson correlations tests were performed. 
In the Twins study, Pearson correlations were corrected for clustered sampling of 
co-twins and within-pair differences were calculated to control for genetic influen-
ces. In addition, Spearman test, partial correlations, multivariate linear regression 
analyses, Student t-test and Mann Whitney test were employed in this work. 
 
Enzyme-linked immunosorbent assay 
Noncompetitive ELISAs were developed to determine the concentration of human 
serum/plasma Angptl3 and Angptl4. A rabbit polyclonal antibody, raised against 
recombinant Angptl3 (aa 17-223) (BioVendor, Czech Republic), was used as cap-
ture antibody whereas a biotinylated sheep IgG, raised against human recombinant 
Angptl3 (aa 17-460) (RnD Systems, Minneapolis, USA), was used for detection. 
Antibodies from the DuoSet Elisa hAngptl4 (RnD Systems, Minneapolis, USA) 
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were used to capture and detect Angptl4. Plates with 96 wells were coated with the 
capture antibodies, blocked and incubated with samples and standards. After the 
incubation with detection antibodies and streptavidin-HRP, the colorimetric reaction 
was performed and plates analyzed at 450 nm. A standardized human serum (for 
Angptl3) or recombinant protein (for Angptl4) was used to construct the standard 
curves. A second order polynomial equation was used to fit the standards and calcu-
late the sample concentrations. 
 
Microarray analysis 
Subcutaneous adipose tissue biopsies were collected under local anesthesia using a 
surgical technique. Total RNA was extracted and the quality was analyzed using the 
2100 Bioanalyzer platform (Agilent Technologies). Adipose tissue transcriptomics 
was obtained using the Affymetrix U133 Plus 2.0 chips. Expression values were 
normalized and analyzed using the GeneSpring GX 7.3 software (Agilent Technolo-
gies). 
 
Lipoprotein lipase activity 
LPL activity was measured as previously described (Huttunen et al, 1975). LPL 
substrate was obtained using [Carboxyl-14C]-Triolein (S.A. 2.2 GBq/mmol, Perki-
nElmer) and glyceryl trioleate emulsified in the presence of gum arabic as previ-
ously described. Samples were incubated with the substrate and human serum (as a 
source for apoC-II, LPL cofactor) for 1 hour at 370C. Reaction was stopped by addi-
tion of 3.25 ml of methanol-chloroform-heptane (1.41:1.25:1.00, vol/vol/vol) and 
0.75 ml of potassium carbonate/borate buffer (pH 10.5). Hydrophilic phase (BSA-
FAs) and hydrophobic phase (triolein) were separated by centrifugation and radioac-
tivity was measured from both fractions by liquid scintillation counting (Wallac LS 
Counter, Turku, Finland).  Activity was expressed as mol of FAs released per hour 
per mg of cell protein. 
 
Fatty acid oxidation 
Fatty acid oxidation was measured using [1-14C]-Palmitic acid (S.A. 2 GBq/mmol, 
ARC 0172A, ARC) or [9,10-3H(N)]-Palmitic acid (S.A. 1.5 TBq/mmol, ART 0129, 
ARC). The oxidation of palmitic acid was analysed by measuring the formation of 
14C-CO2, 3H-H2O and 14C-acids soluble metabolites (Hirschey & Verdin, 2010; 
Rune et al, 2009). Radioactivity was measured by liquid scintillation counting (Wal-
lac LS Counter, Turku, Finland) and values expressed as µmol of FA oxidized per 
minute per mg of cell protein.  
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Primary human myotubes 
Muscle samples for primary human myoblast cultures were obtained from surgical 
open muscle biopsies. Biopsies taken from 6 nondiabetic men were minced and 
digested with collagenase and trypsin.  Satellite cells were isolated, and myoblasts 
proliferated and differentiated for seven days in low serum medium (Al-Khalili et al, 
2003). 
 
Other methods 
Standard methodology such as cell culture, AAV gene delivery, fluorescence mi-
croscopy, Oil Red O staining, lipid measurements, real time PCR, RNA extraction, 
RNA interference, RT-PCR, SDS-PAGE and Western blot, transient transfection 
have been applied in this thesis as described in the original publications. 
 
4.2 Unpublished methods 
 
Adipose tissue lipolysis 
Lipolysis was measured as the rate of glycerol release. In brief, Simpson-Golabi-
Behmel syndrome (SGBS) adipocytes in 12-well plates were incubated in 0.5 ml of 
Krebs-Ringer HEPES (KRH) buffer with 1% fat free BSA in the presence of 1 
µg/ml recombinant human Angptl4 or 100nM isoproterenol or left untreated. Ali-
quots of the KRH buffer were collected at two and four hours and the glycerol con-
centrations were determined by using a fluorimetric assay kit (BioVision). Cell ly-
sates were analysed for protein and intracellular triacylglycerol concentrations to 
normalize the lipolytic signals. Intracellular triacyglycerol concentration was meas-
ured by an enzymatic colorimetric assay (Cobas, Roche/Hitachi).  
 
Campodimele population study 
In Campodimele, a small town located in the province of Latina (Italy), were previ-
ously identified subjects with reduced plasma levels of LDL-cholesterol (LDL-C) 
and ApoB without mutations in apolipoprotein B gene (Fazio et al, 1991). Analysis 
of the ANGPTL3 by re-sequencing revealed the presence of S17X loss of function 
mutation in a total of 55 heterozygotes and 8 homozygotes. Plasma lipids were as-
sayed as previously reported (Campagna et al, 2002). Angptl3 serum levels were 
determined using an ELISA (described in the original publication I) in ANGPTL3 
mutation carriers and in 49 age, gender and BMI-matched non-carriers. Serum sam-
ples were diluted 50-fold and measured in duplicate. Repeated measurements were 
made in homozygotes after 10-fold dilution of serum samples. Post heparin plasma 
was collected 15 minutes after a heparin injection (100 IU/kg body weight). 
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Lipoprotein profile by Fast Phase Liquid Chromatography (FPLC). 
Serum aliquots of 100 μl were applied on a Superose 6HR gel filtration column 
(Pharmacia Biotech, Uppsala, Sweden) at a flow rate of 0.3 ml/min in PBS, pH 7.4 
containing 1mM EDTA. During chromatography fractions (0.6 ml) were collected 
and analysed for cholesterol and triglyceride concentrations using enzymatic col-
orimetric assays (Cobas, Roche/Hitachi). 
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5 RESULTS AND DISCUSSION 
5.1 Angiopoietin-like 3 
5.1.1 Relationship between Angptl3 levels and lipids in plasma  
 
Extensive data derived from mouse studies, in vitro biochemical analyses and hu-
man genetics clearly defined Angptl3 as a modulator of plasma triglyceride levels 
via LPL inhibition (Kersten, 2009). Based on these findings, plasma Angptl3 levels 
are expected to positively correlate with plasma triacylglycerol levels. Analysis of a 
Japanese population suggested that the Angptl3 levels in circulation are not corre-
lated with plasma triacylglycerol levels (Hatsuda et al, 2007). Two other studies 
measured plasma Angptl3 levels and although no correlation with triacylglycerol 
levels has been found the populations were too small to provide convincing evidence 
(Nakajima et al, 2010; Shimamura et al, 2007). To clarify this intriguing Angptl3-
triacylglycerol relationship an in house ELISA was developed using high quality 
affinity purified antibodies (original publication I). Angptl3 ELISA was specific for 
human Angptl3 with detection limit of 1 ng/ml and intra- and inter-assay coeffici-
ents of variation less than 10 %. The in house ELISA was compared with a commer-
cially available kit and Angptl3 levels obtained in 18 subjects were highly correlated, 
p < 0.0001 (original publication I and Figure 12). 
 
 
 
Figure 12. Correlation between in house Angptl3 ELISA and a commercially 
available kit from BioVendor (n=18) (unpublished data).  
r = 0.96 
p<0.0001 
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Serum Angptl3 levels in a random subsample of the Health 2000 Health Examin-
ation Survey (n= 250 subjects) demonstrated high inter-individual variability with a 
distribution skewed to the left, but normalised after logarithmic transformation (Fig-
ure 13). Linear regression analysis revealed a negative correlation between serum 
Angptl3 and fasting triacylglycerols levels (Pearson correlation, r = -0.182, p = 
0.004). This is the opposite what would be expected from the inhibitory effect of 
Angptl3 on LPL activity. Interestingly, this correlation was lost when HDL choles-
terol (HDL-C) and apoA-I levels were used as control variables (partial correlation, r 
= -0.029, p = 0.649) (original publication I). Therefore, the correlation with fasting 
triglycerides might be dependent on Angptl3 effect on HDL-C levels. As Angptl3 
was shown to inhibit also endothelial lipase (EL), it is not surprising that a strong 
correlation with plasma HDL-C levels was found (Pearson correlation, r = 0.224, p < 
0.001) (Jin et al, 2007; Shimamura et al, 2007). These data suggest that plasma 
Angptl3 is a more potent EL inhibitor than LPL inhibitor in humans or that different 
mechanisms of action towards the two lipases is responsible for the observed corre-
lations.   
 
 
 
Figure 13. Angptl3 distribution in a normal Finnish population before (left) and 
after (right) logarithm transformation (unpublished data).  
Elevated plasma levels of triacylglycerol and reduced HDL-C are important com-
ponents of the metabolic syndrome, a cluster of risk factors for CVD and type 2 
diabetes mellitus (Alberti et al, 2009). Therefore, Angptl3 is a possible target for the 
development of new therapeutic strategies to reduce mortality associated with CVD 
and type 2 diabetes mellitus. 
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5.1.2 Angptl3 deficiency and familial combined hypolipidemia (unpub-
lished data)  
 
Further knowledge about the role of Angptl3 in the plasma triacylglycerol metabo-
lism in humans was obtained by studying the familial combined hypolipidemia.  
Elias and colleagues have reported an interesting form of hypobetalipoproteinemia, 
very low plasma apoB levels, not linked to the APOB gene where some of the af-
fected subjects also had very low HDL-C levels (Elias et al, 2000). A decade later, 
Musunuru and collaborators revealed the mystery behind this phenotype using 
exome sequencing (Musunuru et al, 2010). Analysis of two subjects with very low 
apoB and HDL levels revealed two causal non-sense mutations in the first exon of 
ANGPTL3, E129X and S17X. The authors proposed to call this phenotype familial 
combined hypolipidemia (Musunuru et al, 2010).  S17X mutation and the familial 
combined hypolipidemia are highly prevalent in a small town of Campodimele (Lat-
ina, Italy) providing a great opportunity to study Angptl3 function in detail (Fazio et 
al, 1991). Consistent with the S17X variant being a null allele, serum Angptl3 was 
undetectable in homozygous carriers whereas in heterozygotes showed a 42% reduc-
tion compared to non carriers (p<0.0001) (Figure 14).  
 
 
Figure 14. Serum Angptl3 levels according to the number of mutant ANGPTL3 
alleles (unpublished data). Shown are the levels of angiopoietin-like 3 
(ANGPTL3) protein according to the ANGPTL3 genotype. The box plots 
represent the 25% and 75% percentile and whiskers represent the 5-95 
percentiles (delineated by the top and bottom of each box). Outliers fal-
ling below the 5th percentile or above the 95th percentile are represented 
by points below or above the whiskers, respectively. The median levels 
are shown by the middle horizontal line in each box. *p<0.05, Kruskal-
Wallis test and post test analysis using Dunn's Multiple Comparison Test. 
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Consistent with the data obtained in the Health 2000 study (original publication 
I), a reduction in Angptl3 concentration in heterozygotes translated in a significant 
decrease in HDL-C levels (Table 1). S17X homozygotes showed the phenotype 
characteristic for familial combined hypolipidemia, with major plasma lipids dra-
matically reduced (Table 1). 
 
Table 1. Comparison of clinical characteristics and plasma lipids in carriers and 
non-carriers of mutations in the ANGPTL3 gene (unpublished data)1 
 
 Age years  
Gender 
(M/F)  BMI  
TC  
mmol/L  
LDL-C  
mmol/L  
HDL-C 
mmol/L  
TG 
mmol/L  
Non carriers 
(n=339) 
53 ± 
20 161/180 
28 ± 
5 
4.7 ±  
0.8 
2.6 ±  
0.8 
1.6 ±  
0.4 
1 ±  
0.6 
Heterozygotes 
(n=55) 
50 ± 
20 24/31 
29 ± 
5 
4.4 ±  
0.8§ 
2.5±  
0.7 
1.4 ± 
0.4§ 
0.9 ± 
0.5 
Homozygotes 
(n=8) 
65 ± 
14 4/4 
29 ± 
6 
2.4 ±  
0.3* 
1.3 ± 
0.4* 
0.8 ± 
0.2* 
0.4 ± 
0.1* 
 
1Differences between variables were evaluated using Mann-Whitney test. *p< 0.01 for 
comparison between homozygous carriers vs. non-carriers or heterozygous. § p<0.05, for 
comparison between heterozygous carriers vs. non-carriers. 
 
 
This was further supported by analyzing the plasma lipoprotein profile by Fast 
Performance Liquid Chromatography (FPLC) in S17X homozygotes and non-
carriers (Figure 15). These data demonstrate that familial combined hypolipidemia 
segregates as a recessive trait with plasma lipoproteins comprehensively affected 
only by the total deficiency of Angptl3. 
To gain further knowledge about the mechanism by which Angptl3 affects 
plasma lipids levels in humans LPL and hepatic lipase (HL) activities were meas-
ured in post heparin plasma (PHP). Interestingly, PHP-LPL activity was not differ-
ent in heterozygotes compared with non carriers although a significant reduction in 
plasma Angptl3 levels is observed (Figure 16, left panel). Moreover, PHP-LPL ac-
tivity was the same in the lowest Angptl3 quintile (median levels, 42 ng/ml) com-
pared with the highest Angptl3 quintile (median levels, 307 ng/ml) (Figure 17). In 
contrast, in homozygotes the PHP-LPL activity was 3.5-fold higher compared with 
non carriers or heterozygotes (Figure 17, left panel). These data suggest that Angptl3 
is a very potent LPL inhibitor but does not act in a concentration dependent manner 
in vivo, which is in contrast to in vitro data (Shimizugawa et al, 2002). It can be 
speculated that Angptl3 proteolysis rather than plasma Angptl3 levels are important 
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in regulating LPL activity and plasma triacylglycerol levels. A limitation of the 
ELISA used is that it is not known what form of Angptl3 is detected in plasma, full 
length, fragments or all of them. 
 
 
 
 
Figure 15. Serum lipoprotein profiles for non-carriers versus homozygous 
carriers of S17X mutation (unpublished data). Average Fast Phase 
Liquid Chromatography (FPLC) elution profiles for non-carriers (n=2) and 
for homozygotes (n=3) as assessed by cholesterol (Panel A) and triglyc-
erides (Panel B) in elution fractions. Elution positions for VLDL, LDL and 
HDL are depicted.  
Hepatic lipase (HL) displays both triglyceride and phospholipase activity and en-
hances the LDL and HDL catabolism (Olivecrona & Olivecrona, 2010). Angptl3 
was shown to inhibit also HL activity therefore providing mechanistic insights for 
the dramatic reduction in LDL and HDL cholesterol levels observed in Angptl3 
deficiency (Ando et al, 2003; Shimizugawa et al, 2002). However, PHP-HL activity 
was not changed according to the ANGPTL3 genotype, suggesting that in contrast to 
mice, Angptl3 does not inhibit HL activity in humans (Figure 16, right panel). 
The HDL cholesterol phenotype in the Campodimele population confirmed the 
previous observations that Angptl3 and HDL cholesterol levels are positively corre-
lated, most likely by inhibiting the EL activity ((Table 1 and original publication I) 
and (Shimamura et al, 2007)). 
If the changes in plasma triacylglycerol and HDL cholesterol levels can be ex-
plained by the inhibition of LPL and EL lipase activity, the reduction in LDL cho-
lesterol levels remains a complete mystery. One possibility is that Angptl3 acts di-
rectly in the liver to regulate the LDL uptake (Musunuru et al, 2010).
RESULTS AND DISCUSSION 
 
THL — Research 83/2012 48 ROLE OF ANGIOPOIETIN-LIKE 3 AND 4 IN 
TRIACYLGLYCEROL METABOLISM 
 
 
 
 
 
Figure 16. Post heparin (PHP) lipoprotein lipase (LPL) activity (left panel) and 
PHP hepatic lipase (HL) activity (right panel) according to the 
ANGPTL3 genotype (unpublished data). * p < 0.05, Mann-Whitney 
test.  
 
 
 
Figure 17. Angptl3 levels in plasma (left panel) and post heparin (PHP) lipopro-
tein lipase (LPL) activity (right panel) in the lowest (Q1) and highest 
(Q5) quintiles of plasma Angptl3 (unpublished data). * p < 0.05, 
Mann-Whitney test.  
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5.2 Angiopoietin-like 4 
5.2.1 Relationship between Angptl4 levels and lipids in plasma  
 
Data obtained using mouse models and in vitro biochemical analyses provided 
strong evidence that Angptl4 can act as a modulator of plasma triglyceride levels via 
LPL inhibition (Kersten, 2009). Although GWAS studies did not associate 
ANGPTL4 with plasma triacylglycerol, several studies showed that the deleterious 
non-synonymous mutation, E40K, is associated with low plasma triacylglycerol 
levels (Mattijssen & Kersten, 2011). Two small studies utilizing the same commer-
cial ELISA provided contradictory results for the correlation of plasma Angptl4 and 
triacylglycerol levels (Staiger et al, 2009; Stejskal et al, 2008). To clarify the rela-
tionship between the two parameters in humans an in house ELISA for Angptl4 has 
been developed and validated using a previously described protocol based on a 
commercially available antibody (Kersten et al, 2009). The detection limit of the 
assay was 0.1 ng/ml for Angptl4 and the intra- and inter-assay coefficients of vari-
ation were less than 10 % (original publication I). No cross-reactivity was observed 
with human recombinant Angptl3 or with sera derived from different mammalian 
species, mouse, rabbit and bovine. Dilution linearity showed a coefficient of vari-
ation of 9.6 % and the recovery of recombinant protein added to serum was on aver-
age 104 % (original publication I).  
The Angptl4 ELISA was utilised to measure serum Angptl4 levels in a random 
subsample of the Health 2000 Health Examination Survey (n= 250 subjects). 
Angptl4 levels demonstrated high inter-individual variability with a distribution 
skewed to the left and partially normalised after logarithmic transformation (Figure 
18). 
 
 
Figure 18. Angptl4 distribution in a normal Finnish population before (left) and 
after (right) logarithm transformation (unpublished data). 
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Serum Angptl4 levels were positively correlated with free fatty acids (p = 0.044) 
in accordance with the induction of Angptl4 synthesis via PPARs (Kersten et al, 
2009). Interestingly there was no correlation between serum Angptl4 and fasting 
triacylglycerol levels as well as other lipid parameters investigated (original publica-
tion I). Because Angptl4 levels could not be fully normalised and had a very high 
inter-individual variation it might be that this study was too small to firmly establish 
the lipid parameters related to Angptl4 in humans. Therefore a larger study in which 
Angptl4 levels were analysed together with seven ANGPTL4 SNPs was performed 
in 666 subjects of the Northwick Park Heart Study II (original publication II). 
Again, no correlation with triacylglycerol levels was observed but a negative corre-
lation with plasma high-density lipoprotein cholesterol became evident (p<0.01) 
(original publication II, Table 2). The main SNP independently associated with 
higher Angptl4 levels was T266M (p<0.001) possibly by influencing Angptl4 secre-
tion (original publication II, Figure 2). This provided a great opportunity to evaluate 
the relationship between Angptl4 levels, indirectly using T266M variant, and coro-
nary heart disease risk in a very large population. A meta-analysis of 5 studies, with 
more than 4000 cases and 15 000 controls, demonstrated no association of the 
T266M with coronary heart disease risk (original publication II, Figure 3). This 
result was not affected by adjustment for age, gender, and plasma triacylglycerol and 
HDL-C levels.  
All together these data suggest that Angptl4 in circulation is not a relevant modu-
lator of plasma triacylglycerol metabolism in humans, rising questions on the 
mechanism by which Angptl4 inhibits LPL activity. There are several explanations 
for the results obtained. Using Angptl3 as an example, it is conceivable that in hu-
mans the Angptl4 effect on plasma triacylglycerol becomes evident only when non-
functional Angptl4 is synthesised or when the protein is completely lacking in 
plasma (Romeo et al, 2007; Romeo et al, 2009). Another possibility is that Angptl4 
could act at tissue level to fine tune LPL activity with the energy needs of the tis-
sues. In contrast to Angptl3, Angptl4 is also expressed in tissues where LPL is syn-
thesised and therefore it can act as a possible endogenous LPL inhibitor. Moreover, 
Angptl4 is a multifunctional protein and can have various effects acting as con-
founders in the population studies.  
Since Angptl4 protein is cleaved after secretion it is therefore is important to 
know what the ELISA measures, as this could also affect the outcome of the studies. 
It has been previously shown that the antibody used in ELISA recognises full length 
Angptl4 in circulation (Kersten et al, 2009). Analysis of human serum could not 
provide convincing results (data not shown) but the study of purified Angptl4 iso-
forms and cell overexpressing Angptl4 demonstrated that the ELISA used quantifies 
mainly the C-terminal fragment (Figure 19). Although the C-terminal is not relevant 
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for LPL inhibition, the Angptl4 ELISA used in this thesis provided an accurate 
measurement of all Angptl4 isoforms as measured by western blot analysis (original 
publications I, II and III).   
 
 
Figure 19. ELISA affinity for different Angptl4 isoforms (unpublished data). 
Western blot analysis was performed using 50 ng/lane of purified C-
terminal and full length Angptl4 (Purified proteins) as well as using me-
dium from Huh7 cells overexpressing Angptl4 (Media Huh7-Angptl4). 
Two antibodies were tested, a control antibody that recognise all Angptl4 
isoforms (Ctrl Ab) and the antibody used in ELISA (ELISA Ab). Purified 
full length Angptl4 was quantified by ELISA and tested concentration 
(Expected) and actual values obtained by ELISA (Quantified) are pre-
sented.  
5.2.2 Angptl4 as an endogenous LPL inhibitor 
 
To study the capacity of endogenous Angptl4 to inhibit LPL activity an in vitro cell 
model of myotubes was employed. It is established that free fatty acids upregulate 
Angptl4 expression via PPARs and in myotubes Angptl4 is the most highly PPARδ-
induced gene (Kersten, 2009; Staiger et al, 2009).  
Studies using human and mouse myotubes showed that ANGPTL4 gene and pro-
tein expression are increased up to two fold during differentiation of myoblasts into 
myotubes (original publication III, Figure 1 and Figure S1). These results suggest 
that Angptl4 might be part of the myogenic program and could play a role in the 
skeletal muscle energy metabolism. 
Free fatty acids and a specific PPARδ agonist, GW501516, strongly upregulated 
ANGPTL4 gene and protein expression in myotubes ((Staiger et al, 2009) and (IV, 
Figure 2 and 3)). Western blot analyses showed that full-length, C-terminal, and N-
terminal fragments of Angptl4 are secreted from myotubes after PPARδ activation 
(original publication III, Figure 3d). To evaluate if PPARδ activation can inhibit 
LPL activity, myotubes were incubated with GW501516 and heparin releasable LPL 
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activity was quantified. LPL activity was significantly inhibited after 24 hours incu-
bation with GW501516, as compared to non treated cells (original publication III, 
Figure 4a). The GW501516 effect was fast, with a twofold reduction in LPL activity 
already after three hours of incubation (original publication III, Figure 4b). This 
suggests that PPARδ is involved in the rapid regulation of LPL activity at tissue 
level possibly to coordinate the tissue storage and oxidative capacity with the uptake 
of fatty acids (Muoio & Newgard, 2008; Olivecrona & Olivecrona, 2009). To pro-
vide further evidence for this, myotubes were incubated with Intralipid, a stable 
triglyceride emulsion and LPL substrate, in the presence or absence of GW501516. 
As expected, the uptake of fatty acids from Intralipid in myotubes was blocked in 
cells treated with PPARδ agonist (original publication III, Figure 4d and 4e). In 
contrast, the uptake of albumin bound free fatty acids was not affected by 
GW501516, demonstrating that the effect is dependent on LPL activity (original 
publication III, Figure 4d).  
Overexpression of Angptl4 in myotubes resembles the GW501516 action and 
Angptl4 concentration as low as 0.5 ng/ml in medium significantly inhibited LPL 
activity (original publication III, Figure 5a and 5b). Exogenous recombinant 
Angptl4 proved to be less effective in reducing LPL activity (original publication 
III, Figure 5c), suggesting that the expression of Angptl4 and LPL within the same 
cell results in more efficient control of fatty acid uptake. Interestingly, LPL activity 
was also significantly inhibited intracellularly possibly due to an interaction between 
Angptl4 and LPL along the secretory pathway (original publication III, Figure 4c). 
Since GPIHBP1 was suggested to prevent the LPL inhibition by Angptl4 (Sonnen-
burg et al, 2009), the early interaction between the two could provide a mechanism 
relevant also in vivo, in skeletal muscle.  Indeed, administration of GW501516 to 
mice fed a high-fat diet markedly reduced the lipid accumulation in skeletal muscle 
(Tanaka et al, 2003). Although increased oxidation of fatty acids is likely to play a 
major role, it cannot be excluded that reduced uptake due to inhibition of LPL ac-
tivity by Angptl4 also contributes to decreased lipid droplets in skeletal muscle. 
To provide evidence that the inhibition of LPL activity by GW501516 treatment 
is dependent on Angptl4 expression, ANGPTL4 gene was silenced using siRNA 
technology (original publication III, Figure S5). As expected, the ANGPTL4 silen-
cing abolished the inhibitory effect of GW501516 on LPL activity in myotubes (ori-
ginal publication III, Figure 5e). 
Since PPARδ is an important regulator of fatty acid oxidation and Angptl4 is the 
most highly upregulated gene by PPARδ, it is tempting to speculate that Angptl4 
can also be involved in PPARδ-induced fatty acid oxidation (Holst et al, 2003; 
Luquet et al, 2003; Muoio et al, 2002; Tanaka et al, 2003). In contrast to 
GW501516, Angptl4 overexpression had no effect on fatty acid oxidation as meas-
ured by the production of 14C-CO2 and 14C-acid soluble metabolites in myotubes 
(original publication III, Figure 6a). Because Angptl4 was suggested to upregulate 
lipolytic enzymes in C2C12 myocytes, the capacity of Angptl4 to enhance the 
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PPARδ effect on fatty acid oxidation was also evaluated (Staiger et al, 2009). A 
similar induction of palmitate oxidation in control and Angptl4 overexpressing myo-
tubes was observed after incubation with a low dose of GW501516. These data 
strongly suggest that the induction of fatty acid oxidation by PPARδ is independent 
of Angptl4.  
Since fatty acids are products of triacylglycerol-rich lipoprotein (TRL) hydroly-
sis by LPL, it is conceivable that activation of the PPARδ-Angptl4 axis functions as 
a negative feedback mechanism that may serve to protect the muscle fibers from 
lipid overload (Figure 20). The same mechanism was recently suggested to protect 
the heart and macrophages from lipid toxicity in mice fed a high-fat diet (Georgiadi 
et al, 2010; Lichtenstein et al, 2010). Although not directly measured in these stud-
ies, this effect is most likely due to the inhibition of LPL activity by fatty acid-
PPARs-Angptl4 axis. 
 
 
 
Figure 20. Proposed negative feedback mechanism regulating LPL activity in 
the skeletal muscle (original publication III). The working hypothesis is 
that FAs produced by LPL-mediated hydrolysis of VLDL and chylomi-
crons (CM) at luminal surface of the capillaries are rapidly taken up by 
the muscle fibers. Internalized FAs activate PPARδ which in turn upregu-
lates ANGPTL4 gene expression. Angptl4 inhibits LPL activity mainly at 
the surface of the sarcolemma where less LPL will be available to be 
transported at luminal site via the function of GPIHBP1. LPL inhibition by 
Angptl4 occurs to a lesser extent also intracellularly. This mechanism 
may protect the muscle from lipid overload and insulin resistance.  
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5.2.3 Bexarotene inhibits LPL activity via Angptl4 (unpublished data) 
 
In order to regulate gene expression PPARs form an obligatory heterodimer with 
retinoic X receptor (RXR) which binds to PPAR response elements of the target 
genes, such as Angptl4 (Kersten, 2009; Varga et al, 2011). Bexarotene is a potent 
and selective RXR agonist that is currently used in the treatment of cutaneous T cell 
lymphoma and has promising effects in other forms of cancer or dermatologic dis-
orders (Assaf et al, 2006; Farol & Hymes, 2004). More recently, bexarotene was 
shown to rapidly reduce the β-amyloid plaques and reverse cognitive deficits in 
mouse models of Alzheimer's disease (Cramer et al, 2012). Therefore, bexarotene is 
a candidate drug for the treatment of Alzheimer's disease. Unfortunately, the use of 
bexarotene in clinics is limited due to its undesirable increase in plasma triglycerides 
(Assaf et al, 2006). The mechanism underlying this side effect is not completely 
understood. Interestingly, a study performed in rats suggests that bexarotene-
induced hypertriglyceridemia is attributable to elevated VLDL caused by inhibition 
of LPL activity in the muscle (Davies et al, 2001). This is further supported by the 
increased skeletal muscle lipoprotein lipase activity observed in RXRγ deficient 
mice (Haugen et al, 2004). 
 
 
Figure 21. Induction of Angptl4 protein and gene expression by Bexarotene in 
C2/LPL myotubes (unpublished data). Secretion of Angptl4 from 
C2/LPL myotubes was analyzed by Western blot 48 hours after incuba-
tion with DMSO (Control) or 0.2 µM bexarotene (left panel). ANGPTL4, 
LPL and HPRT mRNA levels were measured by real time PCR in C2/LPL 
myotubes incubated with DMSO (Control) or 0.2 µM bexarotene for 24 
hours and values are expressed relative to mouse 36B4 mRNA levels 
(right panel). * p < 0.05, t test.  
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To examine the involvement of Angptl4 in bexarotene-induced reduction in LPL 
activity, C2C12 myotubes stably overexpressing LPL (C2/LPL) were utilized (Poir-
ier et al, 2000). Treatment of C2/LPL myotubes with bexarotene for 24 hours sig-
nificantly increased Angptl4 secretion and gene expression (Figure 21). In contrast, 
LPL gene expression was not significantly changed after bexarotene treatment (Fig-
ure 21, right panel). In agreement with a previous report by Davies et al., bexarotene 
significantly inhibited LPL activity in these cells (Figure 22) (Davies et al, 2001).  
Both silencing of ANGPTL4 gene or inhibition of PPARδ with a specific antagonist, 
GSK0660, abolished the bexarotene effect on LPL activity (Figure 22). These sug-
gest that the inhibition of LPL activity by bexarotene in skeletal muscle is dependent 
on Angptl4 and PPARδ. 
Neutralizing antibodies targeting Angptl4 have been developed in mice and they 
have been shown to efficiently reduce plasma triacylglycerol levels (Desai et al, 
2007). If similar antibodies could be applied to humans they might benefit patients 
who need bexarotene treatment. PPARδ inhibitors, such as GSK0660, can serve as 
an alternative treatment but their use might be limited due to the important role of 
PPARδ in fatty acid metabolism (Holst et al, 2003; Luquet et al, 2003; Muoio et al, 
2002; Tanaka et al, 2003). 
 
 
Figure 22. Inhibition of LPL activity in C2/LPL myotubes is dependent on 
Angptl4 expression and PPARδ activity (unpublished data). C2/LPL 
myotubes transfected with non-targeting siRNA (NT-siRNA) or ANGPTL4 
siRNA were incubated with 0.2 µM bexarotene for 4 hours (left panel). 
C2/LPL myotubes pre-treated with PPARδ antagonist, GSK0660, were 
incubated with 0.2 µM bexarotene for 4 hours (right panel). Heparin re-
leasable LPL activity was quantified and normalised to the protein con-
tent. * p < 0.05, t test.  
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5.2.4 Angptl4 and human obesity 
 
Studies in mice demonstrated that Angptl4 not only inhibits the uptake of fatty acids 
by inhibiting LPL activity (extracellular lipolysis) but also increases the release of 
fatty acids from adipose tissue (intracellular lipolysis) (Gray et al, 2012; Mandard et 
al, 2006; Sanderson et al, 2009). The first observation that Angptl4 might be rel-
evant also for human obesity came from studies in a random subsample of the 
Health 2000 Health Examination Survey (original publication I). Partial correlation 
analysis revealed that serum Angptl4 is inversely correlated with body mass index 
(BMI) (p = 0.008). The inverse relationship between the two parameters was evident 
only in subjects in the age range 30 - 45 years where the levels of Angptl4 were 
significantly decreased (p = 0.03) in overweight subjects as compared to normal 
weight subjects (original publication IV, Figure 3). Because Angptl4 is increased by 
endurance exercise this result could be explained by the difference in physical ac-
tivity between the groups (Kersten et al, 2009). Pearson Chi-Square analysis showed 
that physical activity was not significantly different between the two groups (p = 
0.516).  
These results were further confirmed in monozygotic twins discordant for BMI 
selected from two population-based longitudinal studies, FinnTwin16 and Fin-
nTwin12 (Kaprio, 2006). Twins with an intra-pair difference in BMI greater than 2.5 
kg/m2 were considered as discordant and those with an intra pair difference in BMI 
less than 2.5 kg/m2 were considered as concordant. Serum Angptl4 levels were sig-
nificantly lower in heavier twins compared with leaner co-twins (p=0.04) whereas 
no differences were observed in concordant monozygotic twins (original publication 
IV, Figure 2). Furthermore, Pearson correlations for the intra-pair differences, that 
control for genetic influences, showed that serum Angptl4 levels are negatively 
correlated with BMI (r = -0.27, p = 0.003).  
Further knowledge about the relationship between Angptl4 and obesity in hu-
mans was obtained by analysing the adipose tissue ANGPTL4 mRNA expression. 
ANGPTL4 expression levels in adipose tissue were obtained from genome-wide 
transcriptome analysis performed in fat biopsies obtained from 44 individual mono-
zygotic twins. In the discordant pairs, heavier twins exhibited significantly lower 
ANGPTL4 expression levels as compared to their leaner co-twins whereas similar 
expression levels were observed in concordant twins (original publication IV, Figure 
4).  Moreover, Pearson correlation analyses revealed that ANGPTL4 mRNA levels 
in adipose tissue are negatively correlated with BMI (r=-0.44, p=0.001) (original 
publication IV, Figure 5). In multivariate linear regression analyses including BMI, 
free fatty acids, LDL-C, HDL-C and fasting plasma glucose, only BMI significantly 
explained the variation in at-ANGPTL4 (original publication IV, Table 2). Indica-
tions that Angptl4 could modulate adipose tissue lipolysis also in humans were ob-
tained by analysing the expression levels of several key players involved in this 
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process (Lass et al, 2011). Analysis of the available data on the Affymetrix chips 
showed that ANGPTL4 expression levels are positively correlated with the mRNA 
expression levels of LIPE and ABHD5/CGI-58 (all p<0.01) but not with MGLL or 
G0S2, a recently discovered ATGL inhibitor (Yang et al, 2010) and (original publi-
cation IV, Figure 5). Although these results suggest a role for Angptl4 in intracellu-
lar lipolysis in humans, definite conclusions cannot be drawn based on correlation 
studies and gene expression levels since correlation does not mean causality and 
lipolysis is mainly regulated at the post-transcriptional level (Lass et al, 2011). 
SGBS adipocyte model was employed to directly asses the implication of Angptl4 in 
the human adipose tissue lipolysis (Fischer-Posovszky et al, 2008). The human 
Simpson-Golabi-Behmel syndrome (SGBS) preadipocytes (Figure 23, left panel) are 
efficiently differentiated in the presence of PPARγ agonists and in the absence of 
serum and albumin (Wabitsch et al, 2001). SGBS adipocytes (Figure 23, right panel) 
are a validated model to study the regulation of human adipose tissue lipolysis 
(Fischer-Posovszky et al, 2008). Incubation of SGBS adipocytes with recombinant 
human Angptl4 generated a two fold increase in the glycerol release, standard to 
evaluate intracellular lipolysis (Figure 24). In accordance to this, plasma Angptl4 
was positively correlated with plasma free fatty acid levels during oral glucose toler-
ance test, an estimate of white adipose lipolysis (Staiger et al, 2009). 
Altogether these data strongly support a role for Angptl4 in body fat regulation in 
humans, possibly by stimulating intracellular lipolysis in adipocytes. 
 
 
 
Figure 23. Adipogenic differentiation of Simpson-Golabi-Behmel syndrome 
(SGBS) cells (unpublished data). Conventional light microscopy images 
of SGBS preadipocytes (left panel) and SGBS adipocytes (right panel) af-
ter 14 days of differentiation. Inset represents SGBS adipocytes stained 
with haematoxylin (blue) and Oil Red O (neutral lipid staining).  
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Figure 24. The effect of Angptl4 on intracellular lipolysis in SGBS adipocytes 
(unpublished data). SGBS adipocytes were incubated with 1 µg/ml re-
combinant human Angptl4, 100nM isoproterenol (positive control) or left 
untreated (control). Glycerol release in the medium was quantified at 2 
and 4 hours of incubation. Values are expressed as percentage of se-
creted glycerol from the total intracellular triacylglycerol concentration and 
normalised to the protein concentration. * p < 0.05, t test. 
5.2.5 The effect of insulin on Angptl4 tissue expression 
 
Insulin is a master regulator of carbohydrate and fat metabolism and impaired insu-
lin function or lack of insulin causes diabetes. There are at least three different 
mechanisms by which insulin regulate triacylglycerol metabolism: (i) the secretion 
and uptake of TRLs by the liver (Taskinen, 2003); (ii) LPL mediated extracellular 
lipolysis of TRLs in adipose tissue and muscle (Wang & Eckel, 2009); (iii) inhibi-
tion of intracellular lipolysis and release of fatty acids from adipose tissue (Lass et al, 
2011). Interestingly extracellular and intracellular lipolysis are also modulated by 
Angptl4 (Kersten, 2009). Furthermore, insulin strongly downregulates ANGPTL4 
mRNA expression in both mouse 3T3 L1 adipocytes and in adipose tissue of young 
healthy subjects (Ruge et al, 2011; Yamada et al, 2006).  These data suggest that 
Angptl4 could mediate some of the insulin effects on triacylglycerol metabolism. 
Skeletal muscle and liver cells in culture, as well as human subjects were studied 
to further explore tissue specific regulation of Angptl4 by insulin. Incubation of 
human myotubes, obtained from 6 nondiabetic men, in the presence of insulin for 24 
hours induced a significant increase in cell associated and secreted Angptl4, as com-
pared to non-treated cells (original publication III, Figure 2). This opposite effect in 
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comparison to adipocytes might be related to tissue specific regulation of LPL by 
insulin. A six hour insulin clamp decreased LPL activity in skeletal muscle while in 
adipose tissue LPL activity was increased (Farese et al, 1991). Skeletal muscle LPL 
activity seems to be less sensitive to insulin since four hour insulin clamp had no 
effect on LPL activity in skeletal muscle but significantly increased it in the adipose 
tissue (Ruge et al, 2011). Moreover, it is known that skeletal muscle LPL activity is 
increased during fasting and exercise, both conditions that are likely to increase also 
Angptl4 in skeletal muscle (Kersten et al, 2009; Ruge et al, 2005; Seip & Semenk-
ovich, 1998). It remains to be seen if Angptl4 is a physiological regulator of LPL 
activity in skeletal muscle. An inhibition of the triglyceride uptake in the skeletal 
muscle, that is dependent on LPL activity, was observed in mice fasted for 24 hours 
but not in fed mice (Lichtenstein et al, 2007).  
 
 
Figure 25. Angptl4 levels before and after insulin administration (unpublished 
data). Angptl4 serum levels were measured by ELISA in serum from 
young healthy subjects before (Basal) and after a 4 hours hyperinsuline-
mic euglycemic clamp (Insulin). Results are presented as mean ± SEM of 
three different clamp experiments. * p < 0.05, Wilcoxon matched pairs 
test. 
In contrast to myotubes and adipocytes, Angptl4 secretion in hepatocytes was not 
changed after insulin stimulation although some differences between the cell lines 
used have been observed (original publication III, Figure S2d). Furthermore, there is 
a small, but consistent, decrease in plasma Angptl4 levels after a four hour insulin 
clamp (Figure 25) and (Ruge et al, 2011). The small reduction in plasma Angptl4 
concentration probably reflects the reduction in Angptl4 secretion from adipose 
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tissue, although the contribution of different organs to plasma pool is not known 
(Kersten, 2009).  
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6 CONCLUSIONS AND FUTURE 
PROSPECTS 
It is estimated that by 2050 more than 50% of adults could be clinically obese in 
United Kingdom and United States (King, 2011). The trends for obesity and diabetes 
are expected to increase the prevalence of cardiovascular disease by approximately 
10% over the next 20 years given no changes to prevention and treatment trends 
(Heidenreich et al, 2011). These predictions are likely to be similar in other devel-
oped countries but also in developing countries. Therefore, there is an urgent need 
for better implementation of prevention programs and for development of new 
therapies. Technological breakthroughs in human genetics achieved in the past de-
cade indentified and validated new therapeutic targets but the understanding of their 
mechanisms of action is necessary for developing successful new therapies for car-
diovascular disease. Such possible targets are Angptl3 and Angptl4, and this thesis 
provides insights into their mechanism of regulating triacylglycerol metabolism in 
humans.  
Angptl3 showed striking differences in regulating plasma lipids. Work in this 
thesis suggests that HDL cholesterol is increased by Angptl3 in a concentration 
dependent manner whereas only complete absence of Angptl3 generated a robust 
decrease in plasma triacylglycerol and an increase in LPL activity. The regulation of 
LPL activity by Angptl3 appears to be atypical and studying the role of posttran-
scriptional modifications of Angptl3 such as proteolytic cleavage or glycosylation, 
should provide a deeper understanding of the mechanism. Very little is known about 
how Angptl3 regulate VLDL secretion from liver and release of free fatty acids from 
adipose tissue. Better characterization of its cellular distribution and interaction 
partners will help to understand the complex function of Angptl3 and provide a base 
for the development of future therapies for cardiovascular disease. 
The tissue specific regulation of LPL activity by Angptl4 also deserves further 
investigation. Cell biology and population studies described in this thesis suggest 
that, in humans, Angptl4 does not act as an endocrine regulator of plasma triacylgly-
cerol, but can have subtle roles at the tissue level. In vivo studies using animal mod-
els are the next step for better understanding the tissue specificity of this regulation. 
A limitation to be considered is that, in contrast to humans, high levels of Angptl4 in 
mouse plasma are associated with an increase in plasma triacylglycerol levels.   
Data presented in this thesis clearly indicate Angptl4 as an important regulator of 
adipose tissue lipolysis. For a better understanding of this function, it is important to 
study the interacting partners of Angptl4 at the surface of adipocytes, such as 
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integrins and heparin sulfate proteoglycans. Furthermore, insulin is the main inhibi-
tor of adipose tissue lipolysis and downregulates Angptl4 expression in adipose 
tissue. It is therefore important to study the role of Angptl4 in the insulin effect on 
adipose tissue lipolysis.  
Angptl3 and Angptl4 have been shown to inhibit LPL-dependent extracellular li-
polysis and also to increase intracellular adipose lipolysis suggesting that these two 
processes are closely related. It is important to clearly define whether these effects 
are independent or the increase in adipose tissue lipolysis is secondary to inhibition 
of LPL activity. This can be achieved by studying which region of the proteins is 
responsible for these effects since the N-terminal fragment inhibits LPL activity and 
C-terminal fragment might function as a signalling molecule.  
Because Angptl3 and Angptl4 are secreted proteins that can have a role in the 
crosstalk between different organs, it is important to better understand how the dif-
ferent isoforms of these proteins are transported in plasma. Lipoproteins are poten-
tial transporting platforms for Angptl3 and Angptl4 and might play an important role 
in their function at tissue level. Moreover, it will be interesting to know how dy-
namic is the interaction between Angptls and lipoproteins in fed and fasted state or 
in dyslipidemia. ELISA methods as those described in this thesis provide the means 
for such studies. 
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